Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

Pfizer (PFE.N), opens new tab said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, highlighting its operational efficiency ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.

Pfizer’s effective tax rate on Reported (2) income for the first quarter of 2025 is negative, primarily due to favorable global income tax resolutions in multiple tax jurisdictions spanning ...

Pfizer Inc. (NYSE: PFE) has released its financial results for the first quarter of 2025, showcasing a solid performance despite a challenging market environment. The company also reaffirmed its ...

Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29. Analysts expect the New York-based company to report quarterly earnings at 68 ...

NEW YORK – Amid questions over the financial impact of tariffs and Medicare Part D reform, Pfizer did not meet the consensus Wall Street revenue expectations in the first quarter of 2025 but saw ...

Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, ...

In the latest trading session, Pfizer (PFE) closed at $22.15 ... an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system ...